Menu Search
Equities

Rua Life Sciences PLC

RUA:LSE

Rua Life Sciences PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)10.75
  • Today's Change-0.75 / -6.52%
  • Shares traded558.88k
  • 1 Year change-14.00%
  • Beta1.0001
Data delayed at least 20 minutes, as of Nov 08 2024 16:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Rua Life Sciences PLC had revenues remain flat at 2.18m, though the company grew net income from a loss of 2.00m to a smaller loss of 1.44m. A reduction in the selling, general and administrative costs as a percentage of sales from 125.70% to 116.61% was a component in the net income growth despite flat revenues.
Gross margin81.06%
Net profit margin-65.72%
Operating margin-88.41%
Return on assets-20.82%
Return on equity-24.27%
Return on investment-22.39%
More ▼

Cash flow in GBPView more

In 2024, Rua Life Sciences PLC increased its cash reserves by 164.89%, or 2.45m. Cash Flow from Financing totalled 3.89m or 177.45% of revenues. In addition the company used 1.33m for operations while cash used for investing totalled 85.00k.
Cash flow per share-0.0321
Price/Cash flow per share--
Book value per share0.1157
Tangible book value per share0.1041
More ▼

Balance sheet in GBPView more

Rua Life Sciences PLC appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.59% of the market capitalization can be attributed to its 3.93m and debt could be paid in full if management chose.
Current ratio9.01
Quick ratio8.81
Total debt/total equity0.0542
Total debt/total capital0.0514
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.